Competitor Analysis: P. aeruginosa Vaccines and Therapeutics

Date: June 23, 2010
Pages: 22
US$ 240.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CA98143808CEN

Download PDF Leaflet

Competitor Analysis: P. aeruginosa Vaccines and Therapeutics
Product description

The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules against infection with Pseudomonas aeruginosa as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pseudomonas aeruginosa is much more dangerous to populations who have weak immune systems, the elderly, and those who have been hospitalized for long periods of time. People with cystic fibrosis and with full-blown AIDS frequently die from infections created by the bacteria. Hospital-acquired pneumonia, particularly ventilator-associated pneumonia , causes considerable morbidity and mortality despite antimicrobial therapy and advances in supportive care. It is the second most frequent nosocomial infection and is the major cause of death among hospital-acquired infections.

At present there is no approved vaccine available for prevention of P. aeruginosa infection. Treatment of P. aeruginosa infection is limited to number of antibiotics. With the advent of biotechnology, a number of experimental vaccines and therapeutic antibodies are being evaluated in preclinical and clinical R&D. Peptide and small molecule therapeutics are being developed to fight bacterial infections including those caused by P. aeruginosa.

The report includes a compilation of currently active projects in development of vaccines, antibodies, peptides and small molecules targeting Pseudomonas aeruginosa for prophylaxis and treatment of P. aeruginosa infection. In addition, the report lists company-specific R&D pipelines of P. aeruginosa Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
  • P. aeruginosa Vaccines
  • P. aeruginosa Antibodies
  • P. aeruginosa Peptides
  • P. Aeruginosa Small Molecules
  • P. aeruginosa R&D Licensing Agreements
  • Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines
  • About La Merie
About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Skip to top

Competitor Analysis: CMV Vaccines & Therapeutics US$ 247.00 Aug, 2012 · 23 pages
Competitor Analysis: Anthrax Vaccines & Therapeutics US$ 257.00 Jun, 2013 · 32 pages
Competitor Analysis: HPV Vaccines US$ 180.00 May, 2010 · 18 pages

Ask Your Question

Competitor Analysis: P. aeruginosa Vaccines and Therapeutics
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: